(VIANEWS) – United Therapeutics Corporation (UTHR), Ulta Beauty (ULTA), H&E Equipment Services (HEES) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. United Therapeutics Corporation (UTHR)
15.9% sales growth and 17.92% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $17.75.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.9. Meaning, the purchaser of the share is investing $12.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.92%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
United Therapeutics Corporation’s EBITDA is 4.2.
Sales Growth
United Therapeutics Corporation’s sales growth is 13.6% for the current quarter and 15.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 2.9% and 64.4%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 2.11B for the twelve trailing months.
2. Ulta Beauty (ULTA)
8.6% sales growth and 66.08% return on equity
Ulta Beauty, Inc. operate specialty retail stores selling cosmetics, fragrance, haircare and skincare products, and related accessories and services in the United States. It offers broad assortment of branded and private label beauty products including cosmetics, fragrance, haircare, skincare, bath and body products, professional hair products, and salon styling tools; and salon services, including hair, skin, makeup, and brow services, as well as nail services. The company's private label products comprises Ulta Beauty Collection branded cosmetics, skincare, and bath products, as well as Ulta Beauty branded products; and the Ulta Beauty branded gifts. It also distributes its products through its stores, website, and mobile applications. The company was incorporated in 1990 and is based in Bolingbrook, Illinois.
Earnings Per Share
As for profitability, Ulta Beauty has a trailing twelve months EPS of $23.7.
PE Ratio
Ulta Beauty has a trailing twelve months price to earnings ratio of 17.48. Meaning, the purchaser of the share is investing $17.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 10.73B for the twelve trailing months.
Moving Average
Ulta Beauty’s value is under its 50-day moving average of $454.93 and way under its 200-day moving average of $483.28.
Sales Growth
Ulta Beauty’s sales growth for the next quarter is 8.6%.
Volume
Today’s last reported volume for Ulta Beauty is 206405 which is 77.95% below its average volume of 936146.
Previous days news about Ulta Beauty(ULTA)
- According to Zacks on Tuesday, 29 August, "Here we have highlighted three better-ranked stocks, namely Urban Outfitters, Inc. (URBN Quick QuoteURBN – Free Report) , Ulta Beauty Inc. (ULTA Quick QuoteULTA – Free Report) and American Eagle Outfitters Inc. (AEO Quick QuoteAEO – Free Report) ."
3. H&E Equipment Services (HEES)
8.4% sales growth and 40.17% return on equity
H&E Equipment Services, Inc. operates as an integrated equipment services company. The company operates in five segments: Equipment Rentals, Used Equipment Sales, New Equipment Sales, Parts Sales, and Repair and Maintenance Services. The Equipment Rentals segment provides construction and industrial equipment for rent on a daily, weekly, and monthly basis through a fleet of approximately 42,725 pieces of equipment. The Used Equipment Sales segment sells used equipment through retail sales force primarily from its rental fleet, as well as inventoried equipment that are acquired through trade-ins from equipment customers. The New Equipment Sales segment sells new construction equipment through a professional in-house retail sales force. The Parts Sales segment sells parts for the equipment customers, as well as offers for its rental fleet. The Repair and Maintenance Services segment serves its rental fleet and equipment owned customers, as well as offers ongoing preventative maintenance services to industrial customers. It also provides ancillary equipment support activities, including transportation, hauling, parts shipping, and loss damage waivers. The company's rental fleet consists of hi-lift or aerial work platforms, cranes, earthmoving and material handling equipment, and others. It serves industrial and commercial companies, construction contractors, manufacturers, public utilities, municipalities, maintenance contractors, and various other industrial account customers. As of December 31, 2021, the company had a network of 102 service facilities in the Pacific Northwest, West Coast, Intermountain, Southwest, Gulf Coast, Southeast, and Mid-Atlantic regions of the United States. H&E Equipment Services, Inc. was founded in 1961 and is headquartered in Baton Rouge, Louisiana.
Earnings Per Share
As for profitability, H&E Equipment Services has a trailing twelve months EPS of $4.33.
PE Ratio
H&E Equipment Services has a trailing twelve months price to earnings ratio of 10.38. Meaning, the purchaser of the share is investing $10.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 40.17%.
Yearly Top and Bottom Value
H&E Equipment Services’s stock is valued at $44.93 at 01:22 EST, way below its 52-week high of $56.47 and way above its 52-week low of $26.94.
Volume
Today’s last reported volume for H&E Equipment Services is 155843 which is 28.23% below its average volume of 217150.
Earnings Before Interest, Taxes, Depreciation, and Amortization
H&E Equipment Services’s EBITDA is 2.33.
4. CVS Health (CVS)
7.8% sales growth and 3.81% return on equity
CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
Earnings Per Share
As for profitability, CVS Health has a trailing twelve months EPS of $2.19.
PE Ratio
CVS Health has a trailing twelve months price to earnings ratio of 30.68. Meaning, the purchaser of the share is investing $30.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.81%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 19, 2023, the estimated forward annual dividend rate is 2.42 and the estimated forward annual dividend yield is 3.59%.
5. Option Care Health (OPCH)
7.2% sales growth and 17.39% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $0.86.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 40.23. Meaning, the purchaser of the share is investing $40.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.39%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Option Care Health’s EBITDA is 1.68.
Volume
Today’s last reported volume for Option Care Health is 1422640 which is 50.02% below its average volume of 2846650.
6. Semler Scientific (SMLR)
5.1% sales growth and 30.6% return on equity
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, Semler Scientific has a trailing twelve months EPS of $2.24.
PE Ratio
Semler Scientific has a trailing twelve months price to earnings ratio of 12.09. Meaning, the purchaser of the share is investing $12.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.6%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.5%, now sitting on 64.65M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Semler Scientific’s EBITDA is 2.07.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 10.9% and 14.6%, respectively.
Moving Average
Semler Scientific’s value is higher than its 50-day moving average of $25.57 and under its 200-day moving average of $27.73.
